Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS (ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS (ON) Inhibitors with Ivonescimab in RAS Mutant Tumors — alphai